Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine

Vaccine

Volumn 21, Issue 3-4, 2002, Pages 281-289

  Nolan, Terry ^a   McIntyre, Peter ^b   Roberton, Don ^c   Descamps, Dominique ^d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Immunogenicity; Measles mumps rubella varicella (MMRV); Reactogenicity

Indexed keywords

ANTIBODY; CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; CHICKENPOX VACCINE; MEASLES, MUMPS, RUBELLA, VARICELLA VACCINE; VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; BODY TEMPERATURE; CHILDHOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SCREENING; EDEMA; ERYTHEMA; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INHIBITION KINETICS; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; STATISTICAL SIGNIFICANCE; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; CHICKENPOX; EVALUATION; IMMUNOLOGY; MEASLES; MUMPS; RASH; RUBELLA; SAFETY; SINGLE BLIND PROCEDURE;

ANTIBODIES, VIRAL; CHICKENPOX; CHICKENPOX VACCINE; EVALUATION STUDIES; EXANTHEMA; FEMALE; FEVER; HUMANS; INFANT; MALE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MULTICENTER STUDIES; MUMPS; PAIN; RANDOM ALLOCATION; RUBELLA; SAFETY; SINGLE-BLIND METHOD; VACCINES, ATTENUATED; VACCINES, COMBINED; VIRAL VACCINES;

EID: 0037073537     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00459-0     Document Type: Article

References (15)

1. Centers for Disease Control and Prevention. Measles, mumps, and rubella vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunisation Practices (ACIP). MMWR Morb Mortal Wkly Rep, 47 (No. RR-8), 1998. p. 1-58.
2. National Health and Medical Research Council. The Australian Immunisation Handbook. 7th Ed. Canberra: Australian Government Publishing Service; 2000.
3. Report of the Meeting of the Scientific Advisory Group of Experts (SAGE) of the Children's Vaccine Initiative and the Global Program on Vaccination, Geneva, June 1997. WHO Report No. WHO/GPV/97.05.
4. Bartlett M.J., Burgess M.A., McIntyre P.B., Heath T.C. Parent and general practitioner preferences for infant immunisation: reactogenicity or multiple injections? Aust. Fam. Physician. 28(1):1999;S22-S27.
5. Edwards K.M., Decker M.D. Combination vaccines: hopes and challenges. Pediatr. Infect Dis. J. 13:1994;345-347.
6. Brunell P.A., Novelli V.M., Lipton S.V., Pollack B. Combination vaccine against measles, mumps, rubella, and varicella. Pediatrics. 81:1988;779-784.
7. Vesikari T., Ohrling A., Baer M., Delem A., Bogaerts H., Andre F.E. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children. Acta Paediat. Scand. 80:1991;1051-1057.
8. Dennehy PH, Saracen CL, Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Pediatrics 1994;94(4, Part 1):514-6.
9. Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children. J Infect Dis 1996;173:731-4 [published erratum appears in J Infect Dis 1996 June;173(6):1529].
10. White C.J., Stinson D., Staehle B. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children: Measles, Mumps, Rubella, Varicella Vaccine Study Group. Clin. Infect. Dis. 24:1997;925-931.
11. Centers for Disease Control and Prevention. Prevention of varicella: Recommendations of the Advisory Committee on Immunisation Practices (ACIP). MMWR Morb Mortal Wkly Rep, 45 (No. RR-11), 1996. p. 1-25.
12. Centers for Disease Control and Prevention. Prevention of varicella: Update recommendations of the Advisory Committee on Immunisation Practices (ACIP). MMWR Morb Mortal Wkly Rep, 48 (No. RR-6), 1999. p. 1-5.
13. Centers for Disease Control and Prevention. National, state and urban area vaccination coverage levels among children aged 19-35 months - United States, 2000. MMWR Morb Mortal Wkly Rep, 50(30), 2001. p. 637-41.
14. Berger R., Just M. Interference between strains in live virus vaccines. II. Combined vaccination with varicella and measles-mumps-rubella vaccine. J. Bio. Stand. 16:1988;275-279.
15. Shinefield H, Black SB, Reiseinger KS, Blatter MM, Desrosiers E, Wetzler J, et al. Evaluation of a new formulation of a quadrivalent measles, mumps, rubella, and varicella (MMRV) vaccine in healthy infants. Pediatric Academic Societies and the American Academy of Pediatrics Joint Meeting, Boston, 2000.